about
Inhibition of Mutated, Activated BRAF in Metastatic MelanomaSequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanomaCorrelation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibFactors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastasesNovel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasPreclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.Association between chemotherapy response and rate of disease progression in disseminated melanoma.Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastasesEffective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.Systemic therapy of non-resectable metastatic melanoma.An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs.Assessment of tumour growth and of response to chemotherapy of human melanomas in athymic, nude mice.Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours.Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.Management of intracranial melanomas in the era of precision medicine.Biochanin A induces anticancer effects in SK-Mel-28 human malignant melanoma cells via induction of apoptosis, inhibition of cell invasion and modulation of NF-κB and MAPK signaling pathways.
P2860
Q27860458-763168AB-F7D2-4875-9458-150569983B6FQ33494887-ABB982C6-E453-433C-A0C0-3422B3207061Q33758211-B8D2D42C-D761-41CB-8694-18FFB32532BCQ33942964-9AAB80BD-6E9A-4286-9885-C4AC0E14AA01Q35845352-F19A1ED6-875F-4730-9446-04FA976B8B62Q35975738-46011B8D-F707-475E-8F1C-40C315B86D1BQ35978464-1181DE27-2180-4C1F-9C68-EC391281A7ADQ35982135-0418E535-B935-4656-AD49-DD2E130C1F1AQ35982574-02358B9E-BE19-4F25-BC0A-9EE7A7F0E6FDQ36057973-2431ED87-1D89-4702-BF72-66F02DD291DEQ36187013-CEC1DB2F-78D9-41D7-BCC3-BADD5FC83C87Q36194074-A71D3A6F-3E50-416D-8A1A-31311A660CEDQ36467507-B5F2ED41-E179-49FF-B161-127FF400F364Q36642420-E3954E36-9422-443A-BC75-7EF890A14F5CQ37345234-9A69A983-B5B4-429F-A175-A1D8FED6494FQ38166572-0217A91B-11B5-41F1-9ADD-0CBFB0015A8BQ41477902-B6A7E8A3-0C45-4687-BA28-C1A323A1F482Q41760120-F56ADB99-4206-4E2D-95FF-20C7BD928EB4Q42390557-8B3BE2EB-A6C5-4493-AFA6-9E640913DD47Q42590301-9DC33285-20AA-4AF0-923C-A21D5747F223Q43050485-8F77E6DE-99AA-4305-B993-8750017EB831Q44959749-DB5DC0FF-477C-4144-8B7D-173EED94870EQ47429896-6AC152D8-62C8-4AB5-95F8-4F617B874E6E
P2860
description
1976 nî lūn-bûn
@nan
1976年の論文
@ja
1976年学术文章
@wuu
1976年学术文章
@zh-cn
1976年学术文章
@zh-hans
1976年学术文章
@zh-my
1976年学术文章
@zh-sg
1976年學術文章
@yue
1976年學術文章
@zh
1976年學術文章
@zh-hant
name
DTIC (NSC-45388) in malignant melanoma: a perspective.
@en
type
label
DTIC (NSC-45388) in malignant melanoma: a perspective.
@en
prefLabel
DTIC (NSC-45388) in malignant melanoma: a perspective.
@en
P1476
DTIC (NSC-45388) in malignant melanoma: a perspective.
@en
P2093
P304
P577
1976-02-01T00:00:00Z